User login
Key clinical point: Treatment with erenumab significantly improved functional outcomes in 3 months in patients with episodic migraine refractory to previous prophylactic therapies.
Major finding: At 12 weeks, erenumab significantly improved “Migraine Physical Function Impact Diary”-“Physical Impairment” and “Everyday Activities” scores compared with placebo (treatment difference [TD], −3.5; P = .003 and TD, −3.9; P less than .001, respectively). A significantly higher proportion of patients had a 5 or more point reduction in the Headache Impact Test score from baseline compared with placebo (odds ratio, 2.4; P = .002).
Study details: Data come from the 12-week, double-blind, multicenter, Liberty study involving 246 episodic migraine patients who did not previously benefit from 2-4 prophylactic treatments. They were randomly assigned to receive either erenumab 140 mg (n = 121) or placebo (n = 125) once every 4 weeks for 12 weeks.
Disclosures: The study was supported by Novartis Pharma AG, Basel, Switzerland. S Wen, P Hours-Zesiger, and J Klatt were employees of, and hold stocks in, Novartis. M Lanteri-Minet, PJ Goadsby, U Reuter, and MD Ferrari reported relationships with various pharmaceutical companies and/or research organizations.
Source:Lanteri-Minet M et al. J Neurol Neurosurg Psychiatry. 2021 Jan 5. doi: 10.1136/jnnp-2020-324396.
Key clinical point: Treatment with erenumab significantly improved functional outcomes in 3 months in patients with episodic migraine refractory to previous prophylactic therapies.
Major finding: At 12 weeks, erenumab significantly improved “Migraine Physical Function Impact Diary”-“Physical Impairment” and “Everyday Activities” scores compared with placebo (treatment difference [TD], −3.5; P = .003 and TD, −3.9; P less than .001, respectively). A significantly higher proportion of patients had a 5 or more point reduction in the Headache Impact Test score from baseline compared with placebo (odds ratio, 2.4; P = .002).
Study details: Data come from the 12-week, double-blind, multicenter, Liberty study involving 246 episodic migraine patients who did not previously benefit from 2-4 prophylactic treatments. They were randomly assigned to receive either erenumab 140 mg (n = 121) or placebo (n = 125) once every 4 weeks for 12 weeks.
Disclosures: The study was supported by Novartis Pharma AG, Basel, Switzerland. S Wen, P Hours-Zesiger, and J Klatt were employees of, and hold stocks in, Novartis. M Lanteri-Minet, PJ Goadsby, U Reuter, and MD Ferrari reported relationships with various pharmaceutical companies and/or research organizations.
Source:Lanteri-Minet M et al. J Neurol Neurosurg Psychiatry. 2021 Jan 5. doi: 10.1136/jnnp-2020-324396.
Key clinical point: Treatment with erenumab significantly improved functional outcomes in 3 months in patients with episodic migraine refractory to previous prophylactic therapies.
Major finding: At 12 weeks, erenumab significantly improved “Migraine Physical Function Impact Diary”-“Physical Impairment” and “Everyday Activities” scores compared with placebo (treatment difference [TD], −3.5; P = .003 and TD, −3.9; P less than .001, respectively). A significantly higher proportion of patients had a 5 or more point reduction in the Headache Impact Test score from baseline compared with placebo (odds ratio, 2.4; P = .002).
Study details: Data come from the 12-week, double-blind, multicenter, Liberty study involving 246 episodic migraine patients who did not previously benefit from 2-4 prophylactic treatments. They were randomly assigned to receive either erenumab 140 mg (n = 121) or placebo (n = 125) once every 4 weeks for 12 weeks.
Disclosures: The study was supported by Novartis Pharma AG, Basel, Switzerland. S Wen, P Hours-Zesiger, and J Klatt were employees of, and hold stocks in, Novartis. M Lanteri-Minet, PJ Goadsby, U Reuter, and MD Ferrari reported relationships with various pharmaceutical companies and/or research organizations.
Source:Lanteri-Minet M et al. J Neurol Neurosurg Psychiatry. 2021 Jan 5. doi: 10.1136/jnnp-2020-324396.